智通财经APP获悉,国际脐带血库(CO.US)最近宣布,美国FDA已经批准旗下公司Cellenkos研发新药,开展1b期临床试验的申请,非盲试验CK0804将在那些以鲁索替尼(ruxolitinib)疗法治疗骨髓纤维化且效果不佳的患者中进行。
特别声明:以上内容(如有图片或视频亦包括在内)为自媒体平台“网易号”用户上传并发布,本平台仅提供信息存储服务。
Notice: The content above (including the pictures and videos if any) is uploaded and posted by a user of NetEase Hao, which is a social media platform and only provides information storage services.